Fractional CMO for telehealth: who should actually hire one?

Spencer Stuart has tracked CMO tenure for more than 20 years. Its latest study counted 329 of the Fortune 500 with a C-suite marketing leader, which means 171 of the biggest companies in America decided, on purpose, not to fill the seat. The CMOs who do hold the job average 4.3 years in it, below the C-suite average of 4.9. The biggest companies in the world keep re-deciding whether marketing leadership should be a full-time chair. A telehealth company doing seven figures gets to ask the same question, with less room to be wrong.

The direct answer: a fractional CMO fits a telehealth company that has revenue, a working offer, and no senior owner for its growth decisions. Ad budgets, agency scopes, patient-facing claims, and retention priorities are being decided by whoever happens to be standing closest to them. The seat fixes that. It does not fix a product nobody wants, it does not replace the people who produce the work, and it does not compress the months of testing that sit between a strategy and a result.

What does a fractional CMO for a telehealth company actually own?

Decisions, and the accountability for them. Concretely:

What CAC the margin can carry, and when to stop spending into a leak instead of scaling it.
Which claims go to creative, which get rewritten, and which never leave the building.
Whether the agency's scope matches the actual bottleneck, and what to renegotiate when it does not.
Whether the next dollar buys acquisition or fixes the drop-off that makes acquisition pointless.
What the board hears about growth, and what the numbers can honestly support.

In telehealth, those decisions are tangled with the medicine and with regulators. The claim that converts best is often the one that gets the ad account restricted. The intake question that improves qualification can cross a privacy line. The retention cliff that looks like a marketing failure is sometimes a clinical-expectations failure. A generalist marketing leader treats these as edge cases. In this category, they are the job.

The category also punishes an empty seat. Oral products repriced weight-loss telehealth this year, the major platforms moved from compounded offers to branded manufacturer partnerships, and a wave of state AI-disclosure laws now reaches intake chatbots. Each of those shifted budgets and claims inside a quarter. A growth seat that sits vacant through a six-month executive search is a seat the market fills for you.

One boundary matters more than any of that: the seat is judgment plus accountability, not hands. A fractional CMO decides, sequences, and owns the outcome with you. Your team, your contractors, or your agency still produce the work. If nobody can produce the work, you do not have a leadership gap. You have a capacity gap, and that is a different purchase. Should we hire a healthcare growth agency or build in-house walks through that one.

Why not just hire a full-time CMO?

The usual answer is cost, and it is the least interesting one. Here is the real answer:

From Pranay Parikh, MD:

"Fractional, because the other part is practicing medicine, so I get to see/touch/talk to patients (customers) on a regular basis."

Read that twice, because it inverts the whole pitch. Fractional is not a discounted version of full-time. The other half of the week is the input.

A full-time CMO, however good, stops. Whatever contact they had with patients decays into dashboards, session recordings and a research deck someone else assembled. They learn your market the way every marketer learns a market: secondhand, filtered, and a quarter late. That is the standard arrangement and nobody thinks it is strange, because in most categories the customer is not a patient and there is no other way.

In telehealth there is another way, and it is the thing being sold here. The seat is part-time precisely because the rest of it is spent doing the thing your customers are buying. Not observing it. Doing it. The intake question that reads fine on a wireframe and confuses a real person at 9pm. The side effect that makes month two the cliff. The reason a patient says they tried the drug and it failed when they were never on it. Those arrive as experience, weekly, and they arrive before they show up in your funnel data.

The cost argument is real and it is secondary. As of its May 2024 read, BLS puts median marketing-manager pay in the low $160,000s and median chief-executive pay just over $200,000; a CMO worth the title at a funded telehealth company sits somewhere between the two. Benefits add roughly 40 percent on top of wages across private industry, per BLS employer-cost data. Add recruiting, equity, and the two quarters a senior hire spends earning trust, and year one is a mid-six-figure bet. Treat those as a range and a direction, not a quote. They move.

The bet carries churn risk on top. The 4.3-year average tenure is measured at Fortune 500 companies with mature functions and deep benches. A first CMO at a startup usually turns over faster, and a wrong senior hire costs more than salary. It costs the year of runway you spent finding out.

None of that means never hire one. The full-time seat is right when the work is continuous and the company can absorb both the cost and the risk of being wrong about a person. Until then, a good fractional CMO treats building the case for their own replacement as part of the job: documented strategy, measurement that works, a team a full-time leader can inherit without starting over.

When is a fractional CMO the wrong buy?

Four situations where the answer on the call will be no:

Nothing has ever converted. If the offer has never turned strangers into patients at any price, the need is positioning and message testing, and that is project work with a finish line, not a standing leadership seat.
No one can execute. Decisions with nobody to carry them out die in a document. Get hands first, whether hired or agency, then leadership to direct them.
You want the shortcut. The diagnosis is fast. The work is not. A senior title does not compress creative testing cycles, funnel rebuilds, or the months a retention fix takes to show up in the data. Anyone who tells you otherwise is selling the title, not the outcome.
You want cover. If the seat exists so a number nobody owns has a name attached in the board deck, the engagement fails on schedule.

If the open question is agency versus any of this, the agency readiness audit scores whether your inputs are clear enough for outside help to work at all, and the plain-English agency guide decodes what you would be buying.

What changes when the fractional CMO is a physician?

Off-Label's version of the seat is specific. Pranay Parikh, MD is a dual-boarded internal and obesity medicine physician, a practicing telehealth doctor licensed in all 50 states plus DC, and an operator who co-founded Ascent Equity Group, led its sales and marketing, and helped raise $150 million. That combination changes what the seat catches before it becomes expensive.

A physician in the CMO chair reads a claim the way both reviewers will: the ad platform's and the medical board's. He knows what an intake flow can ask, what it cannot, and what has to happen in the sixty seconds after a patient is told no, because the people an intake screens out are the funnel's highest-stakes moment, not its waste. He can tell whether a month-two retention cliff is a marketing problem or a clinical-expectations problem, because he has managed the medicine on the other side of it. A marketing-only leader escalates those questions to counsel, or guesses. In a regulated category, the guessing is what gets expensive.

To be plain about the limits: this is strategic guidance, not legal advice, and claims, privacy, and licensing questions still need qualified counsel. The point is narrower. Most expensive marketing mistakes in telehealth are not legal questions. They are judgment calls made upstream of the lawyers, and they go better when the person making them has read the chart.

How does an engagement start?

Not with a proposal. With a diagnosis. Marketing Triage routes you in five questions; the free 15-minute call does the same with a person on the other end. From there, engagements take one of three shapes: an advisory pod, a pod with execution oversight, or the full fractional CMO seat. Which shape fits depends on what the diagnosis finds and how much decision-making you need owned, not just reviewed.

There are no prices on this page on purpose. Prices printed on websites expire; scope gets built on the call, month to month, sized to the decisions actually sitting on your desk. Two boundaries are fixed. Off-Label is boutique by design and holds limited client capacity. And it does not work with TRT or peptides companies.

If growth decisions at your company have no senior owner today, that is the conversation to book. Bring the numbers you trust least. Book the 15-minute call.